The Online Investor
Home
Dividends
25 Safe Dividends
Stock Splits
Mergers & Acquisitions
Mega Mergers
Stock Buybacks
Stock Buybacks
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
IPOs
Secondary Offerings
Top 20 Large Caps
Top 20 Biggest ETFs
Insider Buying
Top 25 Low PE Ratios
Analyst Actions
25 Top Analyst Picks
Articles
CAGR Calculator
Dunnan On Dollars
10 Pot Stocks
ETF Center
Knowledge Center
Retirement Center
Advertising Opportunities
Privacy Policy
Disclaimer Statement
PRPH Buyback image

ProPhase Labs, Inc. Buyback

OLI recorded this information on 3/15/2023

Company: ProPhase Labs, Inc.
Buyback: PRPH buyback
$Amount Authorized: $6,000,000
Buyback Details: ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its Board of Directors has authorized a stock repurchase program of up to $6 million in ProPhase Labs' common stock. The Company's previous stock buyback program expired in February 2023. During the past six months, between purchasing stock in the open stock market and retiring shares from stock option exercises, the Company retired a total of 1.2 million shares of common stock.

ProPhase Labs is a company focused on diagnostic and genomic products and services, the development and commercialization of novel drugs, dietary supplements, and compounds, and contract manufacturing. Co. has identified two operating segments. The diagnostic services segment provides SARS-CoV-2 diagnostic information services to a range of customers in the U.S., including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the U.S. and also provides personal genomics products and services.
Open the PRPH Page at The Online Investor »

PRPH — Key Stats (updated 18 hours, 34 minutes ago)
Company Name:  ProPhase Labs Inc
Stock buyback:  PRPH buyback
Website:  www.ProPhaseLabs.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding PRPH:  3
Total Market Value Held by ETFs:  $3.16M
Total Market Capitalization:  $89.00M
% of Market Cap. Held by ETFs:  3.56%
 

Open the PRPH Page at The Online Investor (in a new window) »
May 14, 2024  •  4:59 AM Eastern
PRPH — Current Quote
Quotes delayed 20 minutes

Email EnvelopeFree PRPH Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Avg. Broker Rec.

Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

PRPH Buyback | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.